• Healthcare decisionmaking requires the consideration of multiple criteria beyond those based only on drug efficacy and cost, for the determination of the optimal resource allocation to ensure coverage of the maximum possible needs of the population. 1 • Multicriteria decision analysis (MCDA) structures complex problems into a comprehensive set of criteria that are relevant to establish the value of a drug, allowing systematic and explicit consideration of these to support healthcare decisionmaking. In addition, the MCDA-based EVIDEM framework integrates ethical aspects to promote reflection and achieve accountable and reasonable decisionmaking. 2,3
• The EVIDEM approach proved to be useful specifically in the context of rare diseases where uncertainty around treatment evidence challenges the process of drug evaluation. 
BACKGROUND RESULTS
• Two specialist reviewers (external to CatSalut) identified current PASFTAC processes and drug assessment criteria and compared them against the EVIDEM framework on a criterionby-criterion basis, to explore feasibility of adapting EVIDEM to the PASFTAC context.
• Next, sixteen stakeholders including PASFTAC program personnel (evaluators and decisionmakers), external clinicians/advisors, and patient representatives, participated in a workshop session to field-test the EVIDEM framework. Participants were asked to select the criteria suitable to the context, provide weights to each criterion, and discuss specific needs and adaptation.
• Weight allocation was performed using two different techniques to reduce uncertainty: 8, 9 Five-point weighting technique -non-hierarchical simple 5-point scale (1 = lowest relative importance, 5 = highest relative importance).
Hierarchical Point Allocation (HPA) technique -each participant distributes a total of 100 points between the framework's domains and criteria within each domain, according to their relative importance.
• Data analysis was performed in Microsoft Excel. Weights were normalized to sum up to 1 for each participant.
• Re-test was performed individually by the same participants two months after the workshop. Re-test consistency was assessed by calculating intra-rate correlation coefficients (ICC). 10
METHODS
• EVIDEM provides a feasible and useful framework to optimize current processes for evaluation of complex treatments by CATSALUT and facilitates tackling of ethical dilemmas.
• Further field testing is required to establish the final reference framework, optimization and use in daily practice for CatSalut. 
CONCLUSIONS

OBJECTIVE
• To explore the usefulness and adapt the EVIDEM framework to the process of the PASFTAC (CatSalut) program for complex treatments, including for rare diseases.
• The PASFTAC process is similar to EVIDEM methods in terms of systematic review of evidence, multidisciplinary involvement, and considerations of most aspects that are made explicit in the EVIDEM framework.
• Most of the criteria considered by the standard quantitative section of the EVIDEM framework (MCDA Core Model) were explicitly included in the PASFTAC's reports, except for "Unmet needs", "Comparative patient-perceived health / patient-reported outcomes", "Comparative cost consequences -other medical costs" and "Comparative cost consequences -non-medical costs". Although not structured in individual criteria, the information regarding these topics was included in different sections of the PASFTAC Technical Reports.
• Criteria of the EVIDEM Contextual Tool were not explicitly included in the PASFTAC reports although participants reported considering them for decisionmaking purposes.
• A majority (> 75%) of participants indicated that all EVIDEM quantitative criteria should be maintained. The other participants made the following recommendations:
Consider "Size of affected population" as a low priority to avoid the application of a utilitarian criteria.
Consider "Comparative cost consequences -non-medical costs" in a qualitative perspective since non-medical costs are usually difficult to quantify.
• Regarding the Contextual Tool, participants agreed to remove "Environmental impact" and "Mandate of healthcare system" which were deemed not key criteria for rare diseases, and adapt "Population priorities and access" to clarify disease prevalence.
• The adapted framework is shown in Table below. • Relative weights were similar for both elicitation methods performed (5-points scale and hierarchical point allocation) (Figure below ).
• Highest weights were assigned to the following criteria: "Disease severity" (15%), "Unmet needs" (13%), "Comparative effectiveness", "Type of therapeutic benefit" and "Quality of evidence" (10% each).
• When results were analysed by participant category, results were consistent within the same category. However, discrepancies were found between decisionmakers and patient representative. Decisionmakers prioritised attributes included in the "Economic consequences", "Type of benefit", and "Comparative" domains while "patient representative" considered all the "Economic" criteria as low interest.
• Re-test analyses confirmed robustness of the results. 
